LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Search

Emergent BioSolutions Inc

Cerrado

SectorSanidad

10.09 -1.75

Resumen

Variación precio

24h

Actual

Mínimo

10.07

Máximo

10.21

Métricas clave

By Trading Economics

Ingresos

63M

51M

Ventas

90M

231M

P/B

Media del Sector

8.326

105.69

Margen de beneficios

22.155

Empleados

900

EBITDA

95M

96M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+48.37% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

58M

577M

Apertura anterior

11.84

Cierre anterior

10.09

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Emergent BioSolutions Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 nov 2025, 17:45 UTC

Ganancias
Principales Movimientos del Mercado

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 nov 2025, 17:31 UTC

Ganancias
Principales Movimientos del Mercado

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

16 nov 2025, 23:40 UTC

Charlas de Mercado

Gold Rises on Likely Technical Recovery -- Market Talk

16 nov 2025, 23:36 UTC

Charlas de Mercado

Nikkei May Edge Lower Amid Lingering Worries Over Elevated Tech Valuations -- Market Talk

16 nov 2025, 23:26 UTC

Charlas de Mercado

RBA Policy Meetings May Contain a Trap for Traders -- Market Talk

16 nov 2025, 16:20 UTC

Ganancias

Fed Minutes, Plus Walmart, Target, Home Depot, Nvidia, and More Stocks to Watch This Week -- Barrons.com

15 nov 2025, 09:20 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

15 nov 2025, 09:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

15 nov 2025, 00:08 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14 nov 2025, 23:56 UTC

Adquisiciones, fusiones, absorciones

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 nov 2025, 23:02 UTC

Charlas de Mercado

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 nov 2025, 22:35 UTC

Ganancias
Adquisiciones, fusiones, absorciones

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 nov 2025, 22:32 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 nov 2025, 22:29 UTC

Ganancias

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 nov 2025, 22:00 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 nov 2025, 21:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

14 nov 2025, 21:18 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 nov 2025, 20:27 UTC

Charlas de Mercado

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 nov 2025, 20:23 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 nov 2025, 20:17 UTC

Adquisiciones, fusiones, absorciones

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 nov 2025, 19:29 UTC

Charlas de Mercado
Ganancias

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 nov 2025, 18:44 UTC

Charlas de Mercado
Ganancias

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 nov 2025, 18:27 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 nov 2025, 18:27 UTC

Charlas de Mercado

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 nov 2025, 18:20 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 nov 2025, 17:20 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

14 nov 2025, 17:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

14 nov 2025, 17:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

14 nov 2025, 16:51 UTC

Charlas de Mercado

Starbucks Gets Holiday Sales Lift -- Market Talk

14 nov 2025, 16:48 UTC

Charlas de Mercado

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

Comparación entre iguales

Cambio de precio

Emergent BioSolutions Inc previsión

Precio Objetivo

By TipRanks

48.37% repunte

Estimación a 12 Meses

Media 15 USD  48.37%

Máximo 15 USD

Mínimo 15 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Emergent BioSolutions Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

1

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

4.95 / N/ASoporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
help-icon Live chat